A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
Price : $35 *
At a glance
- Drugs Ponatinib (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 05 Nov 2018 Planned End Date changed from 1 Nov 2019 to 1 Dec 2020.
- 05 Nov 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2019.
- 05 Nov 2018 Status changed from suspended to active, no longer recruiting.